Everything about Ucb Company totally explained
UCB, is a global
biopharmaceutical manufacturer headquartered in
Brussels. It focuses on novel therapeutic solutions for patients with severe diseases treated by specialists, particularly in the fields of
central nervous system disorders (including
epilepsy),
inflammatory disorders (including
allergy) and
oncology.
History
UCB was founded in
1928 by
Emmanuel Janssen, a Belgian businessman. Initially focused on
industrial chemicals, the company also included a small
pharmaceutical division based around
Meurice Laboratories.
In the early 1950s, UCB set up a research centre where new medicines such as Atarax (
hydroxyzine) were developed. Successful sales enabled the pharmaceutical division to expand, and led to the discovery of another important compound, called
piracetam. This was marketed in the 1970s as Nootropil and used to treat memory and balance problems. It remains one of UCB's key products. At this time, UCB was a company focusing on three core areas:
pharmaceuticals,
chemicals and
films.
The success of Nootropil made it possible for UCB to build a modern pharmaceutical site in
Braine-l'Alleud, south of
Brussels (Belgium). There, UCB developed Zyrtec (
cetirizine), a
blockbuster antihistamine. Other important products have followed including Keppra (
levetiracetam), Xyzal (
levocetirizine) and Cimzia (
peg-antiTNF alpha antibody fragment).
At the end of 2002, the chemicals and films divisions were merged and UCB added the
resins,
additives and
adhesives activities of
Solutia, to form the surface specialties division. The films part has since been sold to
Innovia Films (in September 2004). The chemicals division, Methylamines and Derivatives was spun off and later sold to form the company Taminco.
In May 2004, UCB acquired the British biotechnology company
Celltech, followed in March 2005 by the sale of the surface specialties business to
Cytec Industries. By divesting all of its non-pharmaceutical activities, and acquiring Celltech, UCB has transformed itself into a global
biopharmaceutical company.
On
25 September,
2006, UCB announced the purchase of the German pharmaceutical company
Schwarz Pharma for €4.4
billion (External Link
). As of
July 2007 UCB holds approximately 87% of Schwarz's outstanding shares.
Further Information
Get more info on 'Ucb Company'.
|
External Link Exchanges
Do you know how hard it is to get a link from a large encyclopaedia? Well we're different and will prove it. To get a link from us just add the following HTML to your site on a relevant page:
<a href="http://ucb__company.totallyexplained.com">UCB (company) Totally Explained</a>
Then simply click through this link from your web page. Our crawlers will verify your link, extract the title of your web page and instantly add a link back to it. If you like you can remove the words Totally Explained and embed the link in article text.
As long as your link remains in place, we'll keep our link to you right here. Please play fair - our crawlers are watching. Your site must be closely related to this one's topic. Any kind of spamming, dubious practises or removing the link will result in your link from us being dropped and, potentially, your whole site being banned. |
